Navigation Links
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies

MONROVIA, Calif. and INGELHEIM, Germany, Feb. 21, 2012 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies. Under the terms of the agreement, Boehringer Ingelheim will provide all manufacturing and product supply from preclinical through Phase 1 development.  Xencor is responsible for preclinical and clinical studies and retains all development and commercial rights to products under the agreement. Upon successful advancement of clinical programs beyond Phase 1 development, Boehringer Ingelheim has certain manufacturing rights to supply clinical and commercial material to Xencor.

"Xencor has developed a deep portfolio of biosuperior antibodies with the potential for superior clinical and commercial performance, and this collaboration agreement with Boehringer Ingelheim allows us to establish an important relationship with the leading global contract manufacturer of biologics," said Bassil Dahiyat, Ph.D., president and CEO of Xencor.  "Xencor and Boehringer Ingelheim will share the financial risk in early preclinical and clinical development with the incentive of sharing in future success of the programs."

"We are delighted to start this collaboration with Xencor. It reflects one of our new business models in the contract manufacturing in which both parties are enabled to focus on their core competencies," stated Corporate Senior Vice President Simon Sturge at Boehringer Ingelheim Biopharmaceuticals."We are convinced that this creates a win-win situation for both parties."

Xencor's lead biosuperior compound is an anti-TNF antibody engineered using the company's proprietary Xtend™ antibody engineering technology for increasing antibody half-life. Xencor expects to initiate a Phase 1 trial in 2013 potentially resulting in key human pharmacokinetic data validating Xtend technology.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such as Amgen, Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For more information, please visit

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.


More information:

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
4. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
5. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
7. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
8. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
9. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
10. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
11. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Avery Biomedical Devices (ABD), ... to announce the appointment of Anders Jonzon , ... Dr. Jonzon is a ... Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... was a fellow at the Cardiovascular Institute (UCSF). His ...
(Date:11/24/2015)... DALLAS , Nov. 24, 2015  Ascendant Solutions, Inc. ... announced that its Board of Directors has declared a special ... The stock dividend is payable December 14, 2015, to shareholders ... in the form of additional shares of common stock. ... by the Board is a strong endorsement of our confidence ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th ... Assembly and Annual Meeting of the Radiological Society of ... on Nov-29 th through Dec-4 th , in ... its revolutionary whole body CZT digital SPECT/CT solution at the upcoming ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... their Black Friday sale a week early, offering 40% off select bras and ... intimate apparel industry through both mobile fit technology and the latest fashion, quickly ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 25, 2015 , ... ... delivery technologies and development solutions for drugs, biologics, consumer health and global clinical ... will present at the upcoming Clinical Trial Supply East Asia Conference, to be ...
(Date:11/24/2015)... ... 24, 2015 , ... The hospitals and health systems on ... orthopedic care. They have received recognition for excellence from various reputable organizations in ... Becker's Hospital Review selected hospitals for inclusion based on national rankings and awards ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
Breaking Medicine News(10 mins):